Nebulized formoterol fumarate: Dose selection and pharmacokinetics.

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Abstract Text:

To determine a dose of nebulized formoterol fumarate inhalation solution (FFIS) comparable to that of the marketed formoterol fumarate dry powder inhaler (FA, 12mug), two crossover studies were conducted in subjects with COPD. Study 1 was a single-dose, double-blind, double-dummy dose-ranging study in which 47 subjects were randomly assigned to treatment sequences that evaluated the bronchodilatory effects of FFIS 2.5, 5, 10, 20, and 40mug, FA, and placebo over 12h. Mean FEV(1) AUC(0-12) following FFIS treatment ranged from 1.3 to 3.0l/h in a dose-related manner, with equivalent values (2.3l/h) for FFIS 20mug and FA. Results for other spirometric measures, including peak and trough FEV(1) and absolute change in FEV(1) by timepoint, confirmed the comparability of FFIS 20mug and FA. Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20mug (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively). Study 2, a single-dose, open-label crossover study, was conducted to establish the pharmacokinetic (PK) profile of nebulized formoterol and confirm comparability to FA. Thirteen subjects were randomly assigned to treatment sequences with FFIS 10, 20, and 244mug and FA with a 5-14-day washout period between each treatment. Formoterol levels were assessed from blood and urine collected pre-dose and over a 24-36-h period after dosing. Pharmacodynamic (PD) measures included clinical laboratory and ECG measures pre-dose and over a 24-h period post-dose. FFIS 244mug was rapidly absorbed with a T(max) of 12min and t(1/2) of 6.1h. Data from other doses were sporadic due to assay sensitivity. The mean amount excreted (Ae) in urine suggested linear kinetics and confirmed the comparability of FFIS 20mug and FA. Mean serum potassium decreased and mean serum glucose increased transiently in a dose-dependent manner following treatment. No clinically significant ECG changes were observed; mean heart rate increased after treatment with FFIS 244mug by up to 6bpm. Findings from dose-ranging and PK/PD studies confirmed that a 20mug dose of FFIS was comparable to formoterol fumarate delivered by dry powder inhalation (12mug) and established the dose proportionality and linear kinetics of formoterol fumarate delivered by nebulization.

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pulmonary pharmacology & therapeutics

VOLUME: 21

Page Numbers: 818-23

Journal Abbreviation:

ISSN: 1094-5539

DAY: 8

MONTH: 07

YEAR: 2008

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9715279

Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Nebulized formoterol fumarate: Dose selection and pharmacokinetics.

AFFILIATION: Hines VA Hospital, Stritch Loyola School of Medicine, P.O. Box 1485, Hines, IL 60141, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pulm Pharmacol Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Nebulized formoterol fumarate: Dose selection and pharmacokinetics Related Publications

• A morphologic study of adrenal glands with correlations of body size and heart size.
• Analysis of the cardiovascular action of ibogaine hydrochloride.
• Capillary Resistance.
• Fronto-parietal and cerebellar contributions to motor dysfunction in Williams syndrome: A review and future directions.
• Measurement of sarcoplasmic reticulum Ca(2+) ATPase activity using high-performance liquid chromatography.
• Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
• Observations on the Treatment of Rheumatic Fever with Vitamin P.
• Recurrent implantation failure: definition.
• Reduction of respirable silica following the introduction of water spray applications in Indian stone crusher mills.
• Rheumatic Fever and nutrition.
• Studies on the blood pyridoxine of vitamin B6 deficient monkeys.
• The epidemiology of cocaine and opiate abuse in urban Canada.
• Xanthurenic acid excretion in pyridoxine deficient rhesus monkeys.